Trial Profile
A Multicentre, Randomised, Double Blind, Two Arm Parallel Group Study to Evaluate and Compare the Efficacy and Safety of Modified Release Tacrolimus FK506E (MR4) Versus Tacrolimus FK506 in Combination With MMF (Cellcept®) and Steroids in Patients Undergoing Kidney Transplantation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 01 Nov 2017 Results of pooled analysis of NCT00189839 and NCT00717470 trials comparing outcomes with prolonged-release tacrolimus and immediate-release tacrolimus published in the Transplantation Proceedings
- 07 Jan 2011 Primary endpoint 'Acute-transplant-rejection' has not been met
- 01 Jan 2008 Status change from in progress to completed, from clinicaltrials.gov record.